Peel Hunt reissued their buy rating on shares of PureTech Health (LON:PRTC) in a report issued on Thursday, Digital Look reports. The brokerage currently has a GBX 480 ($6.31) price objective on the stock.
Several other equities research analysts have also recently commented on PRTC. Liberum Capital dropped their target price on shares of PureTech Health from GBX 450 ($5.92) to GBX 420 ($5.52) and set a buy rating for the company in a research report on Monday, January 13th. Peel Hunt raised their target price on shares of PureTech Health from GBX 380 ($5.00) to GBX 460 ($6.05) and gave the stock a buy rating in a research report on Friday, November 22nd.
PRTC traded down GBX 2 ($0.03) during trading on Thursday, hitting GBX 303 ($3.99). 80,499 shares of the stock traded hands, compared to its average volume of 71,917. The firm has a market capitalization of $864.67 million and a P/E ratio of -108.21. The company has a debt-to-equity ratio of 31.14, a current ratio of 0.69 and a quick ratio of 0.67. The firm has a 50-day moving average of GBX 287.82 and a 200 day moving average of GBX 268.99. PureTech Health has a 12-month low of GBX 155.50 ($2.05) and a 12-month high of GBX 335 ($4.41).
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Read More: Why does a company issue an IPO?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.